Purpose. The lack of novel antifungal drugs and the increasing incidence and severity of fungal infections are major concerns worldwide. Herein, we tested the activity of the Blad-containing oligomer (BCO), a new antifungal molecule already in use for agriculture, on Malassezia spp. and dermatophytes, the causal agents of human tinea versicolor and tinea pedis. Given the lack of a standard method for Malassezia susceptibility testing and the plethora of published methods, we also developed an improved method for this genus.
INTRODUCTION
Tinea versicolor is a superficial cutaneous mycosis caused by yeasts belonging to the Malassezia genus with a variable prevalence depending on geographic location, ranging from about 1 % in Scandinavian countries [1] to around 50 % in tropical countries [2] . Although these basidiomycetous fungi compose part of the commensal human skin biota, they may play a role in other skin diseases besides tinea versicolor, namely dandruff, atopic eczema, seborrhoeic dermatitis and folliculitis [3] . Studies have so far failed to divide the Malassezia genus into commensal and pathogenic species [4] . Current knowledge suggest that harmless strains may turn pathogenic under specific conditions, such as high temperature and high humidity, long-term use of corticosteroids or immunosuppressants, chemotherapeutic agents, bone marrow transplantation, AIDS, leukaemia and diabetes [5, 6] . Sensitization to Malassezia is most likely a combination of a dysfunctional skin barrier and/or immune system, genetic background and environmental factors [7] . Epidemiological surveys of tinea versicolor, or of any other skin disorder involving Malassezia species, have always been complicated, due to the vast array of methodologies employed by different authors. Indeed, several culture media and isolation conditions are described in the literature, and, most importantly, identification is performed in a jumble of molecular and non-molecular biology-based methods. Taking this into account, it is difficult to draw any reliable conclusions among studies that are conducted in different countries, particularly when they show clear discrepancies concerning the prevailing species. Whether reported differences in the incidence of specific species are explained by geographic or by methodological variations is still a subject of debate [4, [8] [9] [10] . Despite these caveats, Malassezia sympodialis and Malassezia globosa tend to show up as the most prevalent species across different studies [10] .
Skin infections caused by dermatophytes -termed tinea, also known as 'ringworm' -are estimated to affect 15 % of the adult population in industrial countries, and more than 70 % of the world population is expected to experience the disease during their lifetime [11, 12] . Dermatophytes are ascomycetous fungi and comprise three genera: Trichophyton, Epidermophyton and Microsporum. The following species are systematically associated with tinea pedis: Trichophyton rubrum, Trichophyton interdigitale, Trichophyton tonsurans, Epidermophyton floccosum and Microsporum canis [13] . T. rubrum stands as the most common dermatophyte worldwide, with the highest incidence in Europe, followed by T. interdigitale [14] . While T. rubrum is responsible for about 80 % of fungal foot infections in the general population of industrialized countries [15] , T. interdigitale, the human-adapted form of Trichophyton mentagrophytes, is the leading species in people who play sports [12, 16] . The taxonomy of dermatophytes has been a subject of multiple approaches during recent decades, generating an overwhelming number of species based on different biological concepts of species. Although the most recent phylogenetic study of these fungi [17] has described a novel taxonomy and genus delimitation for all dermatophytes, and confirmed the main species with clinical relevance (e.g. T. interdigitale, T. rubrum, T. tonsurans and E. floccosum) at molecular level, it is expected that, in the near future, other species will become common in clinical isolates in light of this new classification system. The chronic and recurrent nature of the skin diseases associated with Malassezia spp., coupled with their increasing involvement in systemic infections, have emphasized the need to know the susceptibility profiles of these species for tailoring of more efficacious treatments [18] . However, due to the specific nutritional requirements of Malassezia spp. [19] , the standard method for testing in vitro antifungal susceptibility of yeasts [20] cannot be used for these species. Significant variation and a broad range of MICs have been reported, depending on both the culture medium used and the inoculum concentration, which hamper comparison of results [21] [22] [23] [24] [25] [26] . Researchers have been challenged to adjust the current standard to these particular species, namely by finding suitable culture media, by adjusting the inoculum size to counteract their slow growth rate, and by altering incubation times and the definition of the MIC end point [27] . These difficulties do not occur for the susceptibility testing of dermatophytes, which have been included in the reference microdilution method for determining the antifungal susceptibility of moulds [28] .
Conventional therapies against systemic fungal infections rely on a very limited number of drugs. For example, in the USA, only 12 molecules from four classes of antifungal drugs are approved [29] and their antifungal activity and mode of action are well reviewed in the literature: four molecules of the azole class (fluconazole, itraconazole, voriconazole and posaconazole), four different formulations of polyene amphotericin B (amphotericin B deoxycholate, amphotericin B lipid complex, amphotericin B colloidal dispersion and liposomal amphotericin B), three molecules from the echinocandin class (caspofungin, micafungin and anidulafungin) and one pyrimidine (5-fluorocytosine) [30, 31] . Antifungal therapy for fungal skin infections is dependent upon the type of infection. Although it is generally assumed that a systemic therapy should only be considered when lesions cover a large skin surface area and fail to clear with repeated treatment using different topical agents [32] , in many cases, a simple oral monotherapy is insufficient to completely eradicate the infection [33] . A combination of both systemic and topical therapies is expected to have better mycological clearance and it has many advantages, namely, it reduces the safety concerns regarding systemic drugs (hepatoxicity) [33] , and the use of different chemical groups allows a wider coverage and prevention of emergence of resistance [34] . There are six classes of antifungal drugs approved for the treatment of dermatophyte onychomycosis: the heterocyclic benzofuran griseofulvin, allylamines (e.g. terbinafine), azoles (itraconazole, efinaconazole, tavaborole), morpholines (e.g. amorolfine), hydroxypyridinones (e.g. ciclopirox) and the oxaborole tavaborole. Griseofulvin was the first Food and Drug Administration (FDA)-approved antifungal for dermatophyte infections, but its use is no longer recommended due to its low efficacy. Oral terbinafine is considered the current systemic treatment for onychomycosis therapy [35] , but oral itraconazole is also widely used. Although fluconazole is not approved in the USA for the treatment of onychomycosis, it is generally used in other countries and also off-label in the USA [36] . Until June 2014, cicloporix was the only topical agent approved for the treatment of onychomycosis, but its efficacy is quite low, limiting its use to the mildest cases or when oral therapy is not tolerated [37] . Similarly, topical amorolfine, which is only approved for use in Europe, is exclusively used in combination regimens due to its limited efficacy [38] . In 2014, two new antifungals were approved by FDA for the topical treatment of onychomycosis: efinaconazole and tavaborole. Efinaconazole is a triazole suited for the treatment of mild-to-moderate onychomycosis that can be used by a broad range of patients due its favourable side-effect profile, low rate of treatment-related adverse effects and low risk for drugdrug interactions [36] . Tavaborole was the first oxaborole antifungal agent approved by FDA. It acts by inhibiting protein synthesis [39] . It has a low risk of systemic side effects, and its safety and efficacy are comparable to other available topical antifungal agents [40] .
Other dermatophyte infections (e.g. tinea corporis, tinea pedis, tinea cruris and tinea capitis) are also treated with topical or systemic antifungal drugs with antidermatophyte activity [41] . Most superficial cutaneous dermatophyte infections can be managed by topical therapy with agents such as azoles and allylamines. Oral treatments with agents such as terbinafine, itraconazole and fluconazole are only used for extensive or refractory cutaneous infections or for infections that extend to the follicles or the dermis [41] . Luliconazole is an imidazole topically related to lanoconazole that has also been approved by FDA in 2013 for topical treatment of tinea cruris, tinea corporis and interdigital tinea pedis. Both imidazoles seem to have an excellent in vitro activity against dermatophytes [42] and they have also been suggested for treatment of invasive aspergillosis caused by either azole-susceptible or -resistant isolates [43] . In the case of Malassezia, topical antifungal agents are used for the management of localized skin disease while extensive disease usually requires the administration of oral itraconazole or fluconazole [44] . However, systemic infections caused by Malassezia spp. are usually treated with liposomal amphotericin B [18] .
Given the systemic side effects of oral agents, the potential drug-drug interactions and the low efficacy and time-consuming regimens of topical drugs, it is clear that there is a need for alternative therapies with new drugs that inhibit novel fungal specific targets. Furthermore, novel resistance profiles of existing drugs are constantly being reported [45, 46] , including the emergence of multi-drug-resistant strains [47] .
Recently, we reported the discovery of a natural 210 kDa glyco-oligomer fungicide, termed Blad (from the Portuguese 'Banda de Lupinus albus doce') -containing oligomer (BCO), that shows potent antifungal activity against both human and phytopathogenic fungi [48, 49] and that is already on sale in the USA for agricultural applications under the tradename Fracture. Studies performed on Candida albicans and Saccharomyces cerevisiae as model fungi demonstrated that BCO acts through a multi-target mode of action [50] . This potentially circumvents the development of resistance, which is usually associated with drugs that strongly inhibit a single reaction/enzyme [51] . Furthermore, metal homeostasis at the host-pathogen interface, which is BCO's primary mode of action [50] , has emerged as a preferential target for the development of new antifungal drugs, because metal chelators seem not to be susceptible to the development of drug resistance [52] . This new mode of action has already been aknowledged by the Fungicide Resistance Action Committee (FRAC), with its inclusion in a new mode of action category, M12, in the 2016 issue of the FRAC Code List for agricultural applications.
The BCO mode of action, combined with its natural origin and the apparent absence of topical toxicity to mammals [50] , also provides a solid basis for its emergence as a novel class of antifungal for topical mycosis. However, no susceptibility studies have been performed using BCO on Malassezia spp. or dermatophytes. In this research, we report on the potent antifungal properties of BCO on Malassezia spp. isolates from tinea versicolor patients and on dermatophyte isolates from tinea pedis patients. We also developed an improved microdilution broth-based method for the susceptibility testing of Malassezia spp.
METHODS Fungal isolation, identification and maintenance
Clinical samples were collected between November 2014 and March 2015 from a group of patients suffering from either tinea versicolor or tinea pedis, and who attended two higher education institutions, and from one dermatology service (Hospital de Santa Maria) in Lisbon, Portugal. The scales from skin lesions were collected with a sterile scalpel blade or curette from affected skin areas, and were first subjected to microscopic examination [10 % (v/v) KOH] before culture and final identification (which occurred in 2015/ 2016). Samples from suspected tinea versicolor skin lesions were cultured in modified Dixon's agar medium (mDixon) [22] , supplemented with chloramphenicol (0.1 g l
À1
) and oxytetracycline (0.1 g l
). Cultures were maintained at 34 C. The isolates were further purified and maintained in mDixon antibiotic-free medium.
The dermatophytes used in this study were isolated from epidermal scrapings obtained from individuals showing signs of tinea pedis, and who were selected among the same population as those suffering from tinea versicolor. Samples from suspected tinea pedis skin lesions were cultured in dermatophyte test medium (DTM; Biom erieux, Marcy-l'Étoile, France), supplemented with chloramphenicol (0.1 g l
) and agar (20 g l À1 )]; the pH was adjusted to 5.5 and the cultures were maintained at 30 C. Dermatophyte growth was detected by DTM culture medium changing colour from yellow to red, due to the production of alkaline metabolites by dermatophytes [53] . The isolates were further subcultured and maintained in Sabouraud dextrose agar (SDA; Oxoid, Basingstoke, UK). Positive cultures for dermatophytes were characterized according to colony and microscopic features, to provide a presumptive species-specific diagnosis.
The definitive identity of all isolates was confirmed by PCR amplification followed by DNA sequencing. DNA from Malassezia isolates was extracted by alkaline lysis [50 µl lysis buffer per sample; 0.25 % (w/v) SDS, 50 mM NaOH] and boiled for 15 min., then thermally shocked by freezing at
À20
C. The resulting suspension was diluted with 250 µl ultra-pure water and subjected to amplification of the D1/ D2 domain of the 26S ribosomal DNA (rDNA) [54] , followed by sequencing of the amplification products. Primers for PCR were NL-1 and NL-4 [54, 55] . DNA from dermatophyte isolates was extracted with the QIAamp DNA Mini Kit (Qiagen, Courtaboeuf, France) and subjected to amplification of the internal transcribed spacer (ITS) region, coding for non-functional rRNA [56] , followed by sequencing of the amplification products. Primers for PCR were ITS1 and ITS4, which allow amplification of the variable sequences ITS1 and ITS2, as well as the DNA sequence coding for the 5.8S ribosomal subunit [57] . Purification of all PCR products was performed using the Wizard SV Gel and PCR Clean-Up System (Promega, Madison, USA). Sequencing was performed at STAB VIDA (Caparica, Portugal). Consensus sequences were compared to reference sequences at GenBank, using BLAST (Basic Local Alignment Search Tool -http://blast.ncbi.nlm.nih.gov/Blast.cgi).
In vitro antifungal susceptibility testing Antifungal agents BCO was extracted and purified as previously described [48] , and stored lyophilized at room temperature. Fluconazole, itraconazole and terbinafine were obtained from their respective suppliers as follows: Sigma-Aldrich (Gillingham, UK), TCI (Oxford, UK) and Discovery Fine Chemicals (Wimborne, UK). Stock solutions were prepared in water for BCO (2 mg ml
À1
) and fluconazole (0.64 mg ml À1 ), or in 100 % DMSO for itraconazole (1.6 mg ml À1 for Malassezia spp. and 0.2 mg ml À1 for dermatophytes) and terbinafine (50 µg ml À1 ), and stored at À80 C until further use. Fiftyfold dilutions of each stock solution were prepared with ultra-pure water. Final concentrations (in the microplaque after 1 : 2 dilution with the inoculum and following a log 2 dilution sequence) ranged from 1000 to 0.977 µg ml À1 of BCO for both Malassezia spp. and dermatophytes; 64 to 0.0625 µg ml À1 of fluconazole, and 16 to 0.0313 µg ml À1 of itraconazole for Malassezia spp.; 0.5 to 0.001 µg ml À1 of itraconazole, and 2.0 to 0.004 µg ml À1 of terbinafine for dermatophytes. One hundred microlitres of each dilution was transferred to multi-well microdilution plates (96 U-shaped wells), such that each row began with the highest concentration while the lowest was in the 10th line. Line 11 contained the DMSO control (when appropriate) and line 12 the ultra-pure water control.
Optimization of conditions for susceptibility testing of Malassezia The currently approved standard for antifungal susceptibility testing of yeasts (M27-A3, CLSI) [19] does not provide guidelines for the specific testing of Malassezia spp. We have, therefore, addressed this issue to predicate our subsequent analysis of antifungal activity. To this end, we tested 12 differently formulated culture media, to substitute the standard culture medium Roswell Park Memorial Institute (RPMI) -1640, namely fatty acid RPMI-1640 [23] , modified Leeming-Notman medium [22] , modified Dixon's broth [47] , SDA supplemented with 1 % (v/v) Tween 80 [24] , RPMI-1640 plus 0.5 % (w/v) ox bile [25] and mDixon [26] . Other culture media were formulated based on the addition to current formulations of well-known supplements that promote Malassezia growth, namely: modified Kimmig fungal agar (38 g glucose l
, 30 g peptone l
, 2 g NaCl l À1 , 10 ml glycerol l , 40 ml olive oil l À1 , pH 5.6). For these tests, the CLSI M27-A3 [20] standard inoculum was increased 100-fold (to 1-5Â10 5 c.f.u. ml
) in order to stimulate the growth of the most fastidious strains and to avoid the interference of this parameter (inoculum size) in the selection of the medium. A group of eight isolates was used in these tests, comprising two representatives of each of the four species isolated from the clinical samples. The most suitable inoculum size for Malassezia was tested only on the most promising culture medium, and comprised three different concentrations: 1-5Â10 3 c.f.u. ml À1 (CLSI M27-A3 standard), 1-5Â10 4 c.f.u. ml À1 and 1-5Â10 5 c.f.u. ml
.
Susceptibility testing of Malassezia
The general guidelines described in CLSI M27-A3 [20] using the broth microdilution method were followed, except for the culture medium composition and inoculum size. Yeast cells were grown on mDixon medium and the inoculum suspension was prepared by selecting fresh colonies that were then resuspended in 5 ml of sterile saline [0.9 % (w/v) NaCl] plus 0.5 % (v/v) Tween 20. The resulting suspension was vortexed until a homogeneous suspension was achieved. In most cases, this suspension showed numerous clumps, so it was necessary to let it stand for a few minutes to obtain a stable optical density reading (OD 640 nm ) in the upper part, which was further used for these tests. Cell density was then adjusted spectrophotometrically to yield an inoculum concentration of 10 6 c.f.u. ml
À1
. The final suspension of inoculum was prepared by dilution in doublestrength broth medium. Each well of the microplaque was inoculated with 100 µl of the spore suspension, and the final concentration of the inoculum was confirmed by colony counting after plating in mDixon. The plates were sealed and incubated at 34 C. This temperature was selected from the range 30-34 C, because some isolates were more fastidious growing at lower temperatures and, for others, the influence of this range was almost imperceptive. The results were assessed after 5, 8 and 12 days of incubation, according to the growth observed in the control well (drug-free). The MIC value was considered as the lowest drug concentration showing absence of growth, as recorded visually, for BCO and itraconazole. For fluconazole, the recommendations of the CLSI M27-A3 standard for end point definition were followed [20] .
Susceptibility testing of dermatophytes
For dermatophytes, the reference method for this group of fungi (CLSI, M38-A2) [28] was used with small adjustments. All isolates were previously grown in potato dextrose agar, PDA (Difco, Oxford, UK) and oatmeal agar (Difco), in order to induce conidia production. A suspension of conidia was prepared in a solution of 0.05 % (v/v) Tween 80 by gently scraping the colony surface with a sterile swab. Concentrations of conidia were determined using a haemocytometer and adjusted to 2Â10 6 spores ml
À1
. Working suspensions of conidia were prepared at 1 : 50 dilution in double-strength RPMI-1640 (reference method of CLSI, M38-A2 guidelines) and double-strength PDB, pH 7.5 (reference culture medium for testing BCO [48] ). Each well of the microplaque was inoculated with 100 µl of the spore suspension, and the final concentration of the inoculum was confirmed after plating in SDA. The plates were incubated at 30 C and the results were assessed typically after 4 days of incubation, or else after 7 days for the slowest-growing isolates. The MIC value was considered as the lowest drug concentration showing absence of growth, as recorded visually.
Susceptibility testing controls
In each susceptibility test, all solutions, diluents and culture media involved were tested separately as sterility controls in separate wells of the microplates. At least three replicates were considered for the results, based on the confirmation of the inoculum concentration.
RESULTS

Fungal isolates
The rDNA sequence-based identification of the isolates is described in Table S1 (available in the online version of this article). The sequence-based identification described in Table S1 was inferred by a high degree of similarity between the query sequence of each isolate and the reference sequences at GenBank (query coverages !99 % and identities !99 %). This was strengthened by an almost absolute consensus between the ranked sequences by BLAST according to the table of the best matches in all of our query sequences. For each isolate, Table S1 describes the accession number of the best match. From a total of 29 samples positive for Malassezia, M. sympodialis comprised the majority of the strains (n=21;~72 %), followed by M. globosa (n=4;~14 %) and the new species Malassezia dermatis (n=2;~7 %) and Malassezia slooffiae (n=2;~7 %). A total of 30 isolates of dermatophytes were identified and distributed as follows: T. rubrum (n=15), T. interdigitale (n=14), E. floccosum (n=1) and M. canis (n=1).
Optimization of conditions for testing BCO against
Malassezia spp. The results were recorded over an observational period of 12 days, i.e. the time required for full growth of the most fastidious isolates. For each strain, the appropriate end-time was chosen as the minimum time required for full growth in the control (no-drug) well. For MIC definition, culture media were selected according to two main criteria: absence of spontaneous turbidity throughout the period of incubation and ability to promote growth of all isolates tested. For this purpose, two isolates each of M. sympodialis, M. globosa, M. dermatis and M. slooffiae (n=8) were grown in 12 different culture media broths: (1) (10) oleic acid PDB, (11) modified PDB and (12) modified SDB, as described in the Methods, for susceptibility testing by the microdilution method. Among all tested broths, only two, mSDB and mPDB, were shown to consistently promote the growth of all strains of Malassezia spp. utilized herein without showing any discernible increase in turbidity during 12 days at 34 C. Broths 5, 6 and 7 failed to promote the growth of all strains, and broths 1, 2, 3, 4, 8, 9 and 10 were hazy and/or turbid, hindering a clear-cut definition of MICs. mPDB was then used to test the most suitable inoculum size for these tests. As shown in Table 1 , the standard inoculum size suggested by the M27-A3 guideline (1-5Â10 3 c.f.u. ml À1 ) proved to be too low to sustain acceptable growth of all Malassezia spp. isolates. Indeed, in some cases, a complete absence of growth was noted. We have thus selected the highest concentration tested in this research (1-5Â10 5 c.f.u. ml
À1
) to estimate MIC, since this yielded faster and more reproducible results among replicates and enabled a shorter incubation time.
Susceptibility of Malassezia spp. and dermatophytes to BCO versus azole derivatives and terbinafine All strains of Malassezia spp. and dermatophytes were tested against BCO, together with two of the drugs most commonly used in the treatment of tinea versicolor (itraconazole/fluconazole) and tinea pedis (itraconazole/terbinafine). Based on our previous data, mPDB and mSDB were the media chosen for testing Malassezia spp. A minimum of three replicates were performed for each isolate/drug, and the inoculum considered valid for a MIC result was 1-5Â10 5 c.f.u. ml À1 (although, for some more fastidious strains, results were accepted for 5Â10 4 -5Â10 5 c.f.u. ml À1 , which accounted for 30 % of the isolates). For dermatophytes, we followed the general guidelines of CLSI standard M38-A2, but used two different culture media: RPMI-1640 (as standard) and PDB (which has already been demonstrated as the most suitable for testing BCO) [48] . Given the highly discrepant molecular weight of BCO (210 000 g ) and terbinafine (291.43 g mol À1 ), we expressed our MIC data in µM (Tables 2, 3, 4 and 5) . This is the only unit that allows a feasible and accurate comparison of potency among molecules with highly divergent molecular weights. However, in order to compare these results to other published data, the same results are also expressed in µg ml À1 in each table. Tables 2 and 3 clearly show that, on a molar basis, BCO had a higher effectiveness (lower MICs) than fluconazole and itraconazole on almost all strains of Malassezia spp. in either mPDB or mSDB. Indeed, with the notable exception of M. dermatis when tested against itraconazole in mPDB (but not in mSDB), lower MICs were always obtained for BCO. For example, for M. sympodialis, the most prevalent Malassezia species in our analysis, the average MIC for BCO tested in mPDB broth was 0.10 µM (range: 0.07-0.15 µM) compared to 12.15 µM (range: 0.82-26.12 µM) for fluconazole and 3.66 µM (range: 0.09-11.34 µM) for itraconazole. Although the doses of BCO required for inhibition of M. globosa (mean 1.23 µM in mPDB and 1.21 µM in mSDB) were higher than for the other species of Malassezia tested here, both fluconazole (with the exception of one strain) and itraconazole completely failed to inhibit M. globosa. Within each species, a lower range of MICs was obtained with BCO as compared to the ranges of fluconazole or itraconazole, and the results were similar for both media (mPDB and mSDB).
With respect to dermatophytes, all strains were highly susceptible to both itraconazole and terbinafine, and no major differences were found between the results obtained using mPDB (Table 4) or RPMI-1640 (Table 5 ). Nevertheless, it should be noted that the results were more uniform within each species in mPDB and that the end-points were much more easily detected in this culture medium. MICs were also lower in this medium, suggesting a higher sensitivity of mPDB for testing itraconazole and fluconazole when compared to RPMI-1640. Clearly, the MICs for BCO on dermatophytes were higher than those for itraconazole and terbinafine, regardless of the species/strain, which is consistent with a lower activity of BCO against this class of fungi. 
DISCUSSION
In vitro susceptibility of Malassezia spp. is a very complicated issue, as there is no standard method available to validate the results. Comparisons among published data on the in vitro susceptibility to antifungals of Malassezia spp. must be made carefully given the discrepancies among inocula density, culture media, temperatures and times of incubation, and the criteria for defining MICs that have been used.
In the current research we tested 12 differently formulated culture media for Malassezia spp., and found that only mPDB and mSDB allowed both the growth of fastidious strains and an easier assessment of MICs. Also, comparative analyses of the MICs obtained using mPDB to those using mSDB indicate that the size of the inoculum has a greater impact on the final MIC than the choice of culture medium per se (data not shown). Nevertheless, mPDB yielded more uniform results and a sharper detection of end-points, which translated into narrower ranges for MICs. In general, the MIC values were also slightly lower in mPDB, suggesting that this medium is more sensitive than mSDB for susceptibility testing of BCO, in particular, and of antifungals, in general. We therefore suggest that a combination of mPDB medium plus a high-density inoculum (i.e. 1-5Â10 5 c.f.u. ml
À1
) provides optimal conditions for testing susceptibilities to antifungals on Malassezia spp.
In this work, we tested the activity of a novel antifungal, BCO, on Malassezia spp. using the optimized susceptibility testing method and compared its efficacy to that of imidazole derivatives currently utilized in the treatment of severe tinea versicolor, namely fluconazole and itraconazole. We found that, on a molar basis, BCO was more effective than either fluconazole or itraconazole on almost all strains of Typically, studies using a lower concentration of inoculum obtain higher susceptibilities and do not detect less susceptible strains [22, 23, 25, 58, 59] . Our results for the azole compounds are in broad agreement with studies employing higher inoculum densities, within the range of those used here, irrespective of the type of culture media [60] [61] [62] . Interestingly, these MICs are also very similar to those determined for BCO against several Candida spp. and Cryptococcus neoformans (0.08-0.15 µM), in PDB [49] . The lower range of MICs for BCO observed within each species suggests a more uniform susceptibility, probably due to the absence of resistance mechanisms that might be active in some strains for azole compounds. In contrast to its efficacy on Malassezia spp., BCO did not prove superior to itraconazole or terfinabine in regard to the common dermatophytes T. rubrum and T. interdigitale.
While the different dermatophyte species show uniform patterns towards the most common antifungal drugs, Malassezia spp. are much more variable, suggesting that correct identification of these species may be important for the selection of specific drugs. In spite of the inherent variability of in vitro susceptibility studies stemming from the lack of a standardized protocol, a general tendency has been observed regarding the most common antifungals (e.g. higher susceptibility of M. sympodialis and higher tolerance of Malassezia furfur, M. globosa and Malassezia obtuse to terbinafine [58] , and fluconazole inactivity against M. globosa and Malassezia restricta [61] ). In our study, it was clear that M. sympodialis, M. dermatis and M. slooffiae were more susceptible to itraconazole than to fluconazole, and that both fluconazole and itraconazole were inactive against M. globosa.
The limited inter-laboratory agreement among studies using diverse techniques for determining antifungal susceptibility definitely hinders acquisition of the mandatory in vitro data required for the establishment of interpretative breakpoints (correlation between in vitro and in vivo results). To date, this correlation has been established neither for Malassezia spp. nor for dermatophytes. Nevertheless, it is usually assumed that higher MICs are indicative of a poor therapeutic response, as in Candida spp., and vice versa [60] . The development of a microdilution method for susceptibility testing of Malassezia spp., as described in this study, and the standard method CLSI M38-A2 for dermatophytes, is a step forward in acquiring sufficient data to define breakpoints for these fungi in the near future.
We have shown herein that the high susceptibility of Malassezia spp. to BCO, when compared to azole compounds, was not reproduced for dermatophytes. This places BCO, a natural 210 kDa glyco-oligomer fungicide, among the list of promising candidates for future therapies for tinea versicolor in the clinical setting, with the marked advantage of it's having a unique mode of action amongst the existing antifungals. Moreover, a novel method was developed for susceptibility testing of Malassezia to antifungals with sustained improvement in comparison to the current methods, overcoming the most frequently reported drawbacks of this test, namely end point definition and growth of the most fastidious strains. The data gleaned through this research may further prove useful for establishing interpretative breakpoints, i.e. clinically useful correlations between results obtained in vitro and in vivo for these species.
Funding information
The funder CEV SA provided support in the form of salaries for authors SM, AC and IP, but did not have any additional role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.
Conflicts of interest
The authors declare that there are no conflict of interest. The authors alone are responsible for the content and the writing of the paper. 
